Clinical Trials Logo
  1. Home
  2. Other
  3. NCT03850769

Neoadjuvant Nab-Paclitaxel and S-1 in Borderline Resectable Pancreatic Cancer

Borderline Resectable Pancreatic Cancer Clinical Trial

Official title:
Prospective Phase II Single-arm Study of Neoadjuvant Nab-Paclitaxel and S-1 in Patients With Borderline Resectable Pancreatic Cancer

Clinical Trial Summary

This study was a single-arm multicenter prospective phase II clinical study, designed to evaluate the efficacy and safety of neoadjuvant nab-paclitaxel combined with S-1 in patients with borderline resectable pancreatic cancer. A total of 60 subjects who meet the criteria will receive neoadjuvant chemotherapy of nab-paclitaxel and S-1, for a maximum of 4 cycles prior to pancreatectomy. The primary endpoint is R0 resection rate, the secondary endpoints include overall survival and response rate.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03850769
Study type Interventional
Source Peking Union Medical College Hospital
Contact TaiPing Zhang, MD
Phone 13520132976
Email Tpingzhang@yahoo.com
Status Recruiting
Phase Phase 2
Start date May 1, 2019
Completion date April 2022
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT04617821 - AG vs mFOLFIRINOX as Neoadjuvant Therapy for Borderline Reseactable and Locally Advanced Pancreatic Cancer Phase 3
Suspended NCT04090463 - IORT on Borderline Resectable Pancreatic Cancer Phase 2
Terminated NCT04698915 - Phase 2b Study of GC4711 in Combination With SBRT for Nonmetastatic Pancreatic Cancer Phase 2
Not yet recruiting NCT03443921 - Divestment for Artery-involved Pancreatic Cancer N/A
Recruiting NCT06345300 - NALIRIFOX in Combination With Camrelizumab for BRPC: a Prospective, Exploratory Study Phase 2
Not yet recruiting NCT06384560 - Neoadjuvant Triple Treatment for Borderline Resectable Pancreatic Cancer (PREOPANC-5) Phase 1/Phase 2
Active, not recruiting NCT02717091 - Neoadjuvant FOLFIRINOX or Nab-paclitaxel With Gemcitabine for Borderline Resectable Pancreatic Cancer Phase 2
Terminated NCT02241551 - Phase II Neoadjuvant Chemotheraphy (Gemcitabine and Nab-Paclitaxel vs. mFOLFIRINOX) and Sterotatic Body Radiation Therapy for Borderline Resectable Pancreatic Cancer Phase 2
Not yet recruiting NCT06387810 - Irinotecan Liposome II in Combination With 5-FU/LV and Oxaliplatin in Perioperative Treatment of Borderline Resectable Pancreatic Cancer Phase 2
Recruiting NCT04855331 - Laparoscopic Versus Open Pancreatoduodenectomy Following Neoadjuvant Chemotherapy for BRPC N/A